

REMARKS

All outstanding requirements will now be addressed in the order they appear in the Office Action mailed August 12, 2008.

Claim Rejections – 35 USC § 112

Claims 20 and 21 stand rejected under *35 USC § 112*, first paragraph, because the specification, while being enabling as to inhibiting casein kinase 2 activity in a patient in the need of such treatment whereby human leukemia is treated, allegedly does not reasonably provide enablement for inhibiting casein kinase 2 activity in a patient in the need of such treatment broadly. Applicant has amended claim 20 as kindly suggested by the Examiner solely to expedite prosecution of the allowed claims. Withdrawal of the rejection is respectfully requested over the claims as amended. The scope of the claims has not been narrowed as a result of this amendment. Applicant reserves the right to prosecute claims similar or identical in scope to claims 20-21 in their preamended form.

CONCLUSION

In view of the foregoing amendments and remarks, Applicants submit that the pending claims are in condition for allowance. Early and favorable reconsideration is respectfully solicited. Should an extension of time be required, Applicants hereby petition for same and request that the extension fee and any other fee required for timely consideration of this submission be charged to **Deposit Account No. 503182**.

Customer Number: **33,794**

Respectfully Submitted,

/Matthias Scholl/

Dr. Matthias Scholl, Esq.
Reg. No. 54,947
Attorney of Record

Date: October 30, 2008